Introduction to Alzheimer's Treatments

Two drugs have gained FDA approval for treating early-stage Alzheimer's disease, targeting the removal of beta amyloid plaques in the brain. Both drugs require intravenous infusion and come with a significant cost of over $25,000 per year. While effective in clearing amyloid, the drugs only moderately slow the progression of symptoms, showcasing benefits that can vary widely among individuals. This uncertainty often drives patients to try these medications despite the risks involved, including potential severe side effects like brain swelling.